NURO NeuroMetrix Inc.

NeuroMetrix Teams Up with U.S. Pain Foundation to Raise Awareness of Chronic Pain

In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation, a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the issues impacting the chronic pain community. During September, NeuroMetrix will donate a portion of sales of the company’s Quell® Wearable Pain Relief Technology™ to the U.S. Pain Foundation.

Through this partnership, NeuroMetrix will also offer a limited edition Quell Pain Awareness Bundle, featuring educational materials and a Pain Warrior bracelet from U.S. Pain. In addition to the Starter Kit collaboration, participants in the U.S. Pain Foundation’s “30-Day Challenge” social media campaign will have an opportunity to win prizes, including a Quell device, during the month of September.

“Although a third of Americans are living with chronic pain, those outside of this community often struggle to understand its significant and varied impact,” said Shai Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “This month, together with the U.S. Pain Foundation, we hope to bring greater visibility to the devastating effects of chronic pain as part of our mission to enable those living with pain to reclaim their lives. They can’t do it alone, and as we help in providing new technology solutions for widespread pain relief, we also strive to empathize and give those with chronic pain a greater voice.”

“We are committed to educating the public about drug-free, alternative treatments for chronic pain, making this partnership with NeuroMetrix a natural fit,” said Paul Gileno, President and Founder of the U.S. Pain Foundation. “By building awareness for this community and the treatment options that are available to them, we can help to increase access to quality care and empower those living in pain.”

As part of its Pain Awareness Month initiatives, NeuroMetrix will launch a four-week series on its blog, LivingQuell, to dig deeper into the issues surrounding the chronic pain community and share new data revealed from a survey the company issued in partnership with BackerNation. Weekly topics will cover a variety of issues, including the cost of living with pain and the ripple effects of pain. LivingQuell was launched earlier this year to provide an online resource for people affected by chronic pain - as well as the rapidly growing user base of the company's Quell Wearable Pain Relief Technology.

Those interested in purchasing a limited edition Pain Awareness Quell Starter Kit Bundle in September should visit Quellrelief.com

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.

About the U.S. Pain Foundation

U.S. Pain Foundation is a 501(c)(3) organization dedicated to improving the lives of people living with chronic conditions that cause pain. With a mission to empower, support, inform, and advocate at the state and federal level, U.S. Pain focuses on protecting patient rights, enhancing access to effective care, advancing research, reducing stigma, and promoting emotional and physical wellness.

EN
29/08/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeuroMetrix Inc.

Neurometrix Inc: 1 director

A director at Neurometrix Inc sold 20,000 shares at 13.560USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable T...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle. "We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is co...

 PRESS RELEASE

NeuroMetrix Closes $3.5 Million Equity Offering

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share. The Company’s common stock closed on October 30, 2017 at $1.80 per share. Proceeds of the offering will be used for commercialization of Quell®, the Company's over-the-counter wearable device for relief of chronic pain and for general work...

 PRESS RELEASE

NeuroMetrix Reports Q3 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2017. The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions. The Company’s primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain. The Company also has a diagnostic business based on its DPNCheck® product, which is a point-of-care test that pro...

 PRESS RELEASE

NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Resu...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 84863406. Internationally, the co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch